The present invention is directed to the compounds of Formula (I) - inhibitors of LRRK2 The inhibitors described herein can be useful in the treatment of diseases or disorders associated with LRRK2, such as Parkinson disease (PD) In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting LRRK2, methods of treating diseases or disorders associated with LRRK2, and methods of synthesizing these compounds.
[EN] POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] COMPOSÉS POLYCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017100662A1
公开(公告)日:2017-06-15
The present disclosure is directed to compounds of Formula (I) as Bruton's kinase inhibitors and their preparation, as well as compositions comprising compounds of Formula (I).
Inhibitors of Bruton's tyrosine kinase and methods of their use
申请人:JANSSEN PHARMACEUTICA NV
公开号:US10689396B2
公开(公告)日:2020-06-23
The present disclosure is directed to compounds of formula I′ and methods of their use and preparation, as well as compositions comprising compounds of formula I′.
本公开涉及式 I′化合物及其使用和制备方法,以及包含式 I′化合物的组合物。
Inhibitors of Bruton's tyrosine kinase and method of their use
申请人:JANSSEN PHARMACEUTICA NV
公开号:US10800792B2
公开(公告)日:2020-10-13
The present disclosure is directed to compounds of formula I′ and methods of their use and preparation, as well as compositions comprising compounds of formula I′.
本公开涉及式 I′化合物及其使用和制备方法,以及包含式 I′化合物的组合物。
POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE
申请人:Janssen Pharmaceutica NV
公开号:EP3386991A1
公开(公告)日:2018-10-17
INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE